Retirement Systems of Alabama Has $22.21 Million Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Retirement Systems of Alabama lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 66,853 shares of the company’s stock after acquiring an additional 108 shares during the period. Retirement Systems of Alabama owned approximately 0.22% of Medpace worth $22,211,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. R Squared Ltd bought a new position in Medpace during the fourth quarter worth about $30,000. Stone House Investment Management LLC acquired a new position in shares of Medpace in the 3rd quarter worth approximately $33,000. Ashton Thomas Securities LLC acquired a new position in shares of Medpace in the 3rd quarter worth approximately $37,000. Capital Performance Advisors LLP bought a new position in shares of Medpace during the 3rd quarter worth approximately $46,000. Finally, True Wealth Design LLC boosted its stake in Medpace by 16,800.0% in the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after buying an additional 168 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

NASDAQ:MEDP opened at $360.97 on Friday. The stock’s fifty day moving average price is $343.17 and its two-hundred day moving average price is $350.31. The company has a market cap of $11.22 billion, a price-to-earnings ratio of 31.61, a P/E/G ratio of 1.79 and a beta of 1.36. Medpace Holdings, Inc. has a 52-week low of $301.81 and a 52-week high of $459.77.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. TD Cowen dropped their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. William Blair reissued an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Robert W. Baird raised their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Finally, Redburn Atlantic started coverage on Medpace in a report on Monday, October 14th. They issued a “buy” rating and a $404.00 target price on the stock. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.